Diabetes and weight loss drug advertising tops $1B on strength of GLP-1 brand spending

The new class of GLP-1 drug brands is driving diabetes and weight loss prescription drug advertising spending, pushing the combined category to more than $1 billion last year, and with no end in sight for 2024.

Last year’s boost was a more than 50% increase over diabetes and weight loss drug media spending the previous year, according to ad intelligence company MediaRadar. Four GLP-1 brands — Mounjaro, Ozempic, Rybelsus and Wegovy  — accounted for more than $809 million of the more than $1 billion spend, according to MediaRadar’s data. The remaining spending came from other prescription diabetes brands.

Preview

来源: EndPoints

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP

LOG IN

BECOME A PREMIUM SUBSCRIBER

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。